drugset / Trial / NCT02254720
Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers
RandomizedParallel-groupSingle-blindTreatment
Summary
Evaluation of safety, tolerability and pharmacokinetics of single rising intravenous doses of BEA 2180 BR; additional exploration of metabolism following inhalation
Timeline
- Start
- 2006-09
- Primary completion
- 2006-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | 2.5 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 7.5 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 25 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 50 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 100 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 200 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 350 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 500 ug | Intravenous |
| Subject | BEA 2180 BR | Unknown | 1600 ug | Intravenous |
Indications
No indication recorded.